S. Falcon
About
S. Falcon is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, S. Falcon has authored 24 papers receiving a total of 977 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Cancer Research and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Falcon's work include Breast Cancer Treatment Studies (8 papers), Cancer Treatment and Pharmacology (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). S. Falcon is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), Cancer Treatment and Pharmacology (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). S. Falcon collaborates with scholars based in Peru, United States and Russia. S. Falcon's co-authors include Vladimir Moiseyenko, В. А. Горбунова, Jaffer A. Ajani, Mikhail Lichinitser, Ihor Vynnychenko, G. Bodoky, István Láng, August Garin, W. Rodriguez and Daniel P. Petrylak and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.
In The Last Decade
S. Falcon
24 papers receiving 957 citations
Hit Papers
Peers
S. Falcon
Paul Nyandoto Finland
G. Kurteva United States
Sarita Dubey United States
Elena Elimova Canada
Run‐Cong Nie China
Dieter Köberle Switzerland
Woo Sun Kwon South Korea
Anwar Tarabichi Germany
Akitaka Makiyama Japan
Shuqiang Yuan China
Citations per year, relative to S. Falcon S. Falcon (= 1×)
peers
Paul Nyandoto
Countries citing papers authored by S. Falcon
Since
Specialization
Citations
This map shows the geographic impact of S. Falcon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Falcon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Falcon more than expected).
Fields of papers citing papers by S. Falcon
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by S. Falcon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Falcon. The network helps show where S. Falcon may publish in the future.
Co-authorship network of co-authors of S. Falcon
This figure shows the co-authorship network connecting the top 25 collaborators of S. Falcon. A scholar is included among the top collaborators of S. Falcon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Falcon. S. Falcon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Falcon, S., et al.. (2023). Anticuerpos monoclonales conjugados a drogas en cáncer de mama avanzado/metastásico. 62(1). e427–e427.
2.
Neciosup, Silvia P., et al.. (2021). Adaptation of international coronavirus disease 2019 and breast cancer guidelines to local context. World Journal of Clinical Oncology. 12(1). 31–42.
3.
Gómez, Henry, Enrique Bargalló‐Rocha, C Allemand, et al.. (2021). Practice-Changing Use of the 21-Gene Test for the Management of Patients With Early-Stage Breast Cancer in Latin America. JCO Global Oncology. 7(7). 1364–1373.
4.
Jackisch, Christian, Roberto Hegg, Daniil Stroyakovskiy, et al.. (2016). HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up. European Journal of Cancer. 62. 62–75.
5.
Motzer, Robert J., Carlos H. Barrios, Tae Min Kim, et al.. (2013). Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 31(15_suppl). 4504–4504.
6.
Ajani, Jaffer A., G. Bodoky, Vladimir Moiseyenko, et al.. (2012). Non Inferiority Analysis of Multicenter Phase III Comparing Cisplatin/S-1 (CS) with Cisplatin/5-Fu (CF) as First-Line Therapy in Patients with advanced Gastric Cancer (FLAGS): Methodology and Results. Annals of Oncology. 23. ix224–ix225.
7.
Hegg, Roberto, Tadeusz Pieńkowski, Elżbieta Starosławska, et al.. (2012). Immunogenicity of Trastuzumab Intravenous and Subcutaneous Formulations in the Phase III Hannah Study. Annals of Oncology. 23. ix103–ix103.
8.
Jackisch, Christian, Daniil Stroyakovskiy, Susanne Muehlbauer, et al.. (2012). 1BA Subcutaneous Administration of Trastuzumab in Patients with HER2-positive Early Breast Cancer: Results From the Phase III Randomised, Open-label, Multi-centre Neoadjuvant-adjuvant HannaH Study. European Journal of Cancer. 48. S37–S37.
9.
Falcon, S., et al.. (2011). Lymphopenia as a predictive factor of responsiveness to preoperative treatment in patients with locally advanced breast cancer.. Journal of Clinical Oncology. 29(15_suppl). e21096–e21096.
10.
Falcon, S., et al.. (2011). Lymphopenia and breast cancer subtypes as prognostic factors in patients with locally advanced breast cancer.. Journal of Clinical Oncology. 29(15_suppl). e21100–e21100.
11.
Ajani, Jaffer A., W. Rodriguez, G. Bodoky, et al.. (2010). Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial. Journal of Clinical Oncology. 28(9). 1547–1553.
12.
Sternberg, Cora N., Daniel P. Petrylak, Oliver Sartor, et al.. (2009). Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial. Journal of Clinical Oncology. 27(32). 5431–5438.
13.
Martín, Miguel, Maria Błasińska-Morawiec, S. Falcon, et al.. (2009). A Multicenter, Single-Arm Phase II Study of Pemetrexed Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer. Clinical Breast Cancer. 9(3). 155–160.
14.
Gómez, Henry, Claudia Castañeda, S. Falcon, et al.. (2009). A phase I-II trial of Ispinesib, a kinesin spindle protein inhibitor, dosed every two weeks in patients with locally advanced or metastatic breast cancer previously untreated with chemotherapy for metastatic disease or recurrence.. Cancer Research. 69(2_Supplement). 2148–2148.
15.
Ajani, Jaffer A., G. Bodoky, Vladimir Moiseyenko, et al.. (2009). Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. Journal of Clinical Oncology. 27(15_suppl). 4511–4511.
16.
Falcon, S., et al.. (2008). A phase I-II open-label trial of ispinesib on an alternate dosing schedule in chemotherapy-naive patients with locally advanced or metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1143–1143.
17.
Sternberg, C., Daniel P. Petrylak, Fred Witjes, et al.. (2007). Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. Journal of Clinical Oncology. 25(18_suppl). 5019–5019.
18.
Beltrán, Brady, et al.. (2005). Clinical characteristics of lymphomatous form of Adult T cell lymphoma-leukemia in Peru. Journal of Clinical Oncology. 23(16_suppl). 6728–6728.
19.
Gómez, Henry, et al.. (2001). A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: A preliminary report. Seminars in Oncology. 28(3H). 57–61.
20.
Gómez, Henry, Carmen Kahatt, S. Falcon, et al.. (2001). A Phase II Study of Neoadjuvant Gemcitabine Plus Doxorubicin in Stage IIIB Breast Cancer: A Preliminary Report. Seminars in Oncology. 28(3 Suppl 10). 57–61.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Paul Nyandoto Breakdown of academic impact, for papers by G. Kurteva Breakdown of academic impact, for papers by Sarita Dubey Breakdown of academic impact, for papers by Elena Elimova Breakdown of academic impact, for papers by Run‐Cong Nie Breakdown of academic impact, for papers by Dieter Köberle Breakdown of academic impact, for papers by Woo Sun Kwon Breakdown of academic impact, for papers by Anwar Tarabichi Breakdown of academic impact, for papers by Akitaka Makiyama Breakdown of academic impact, for papers by Shuqiang Yuan